Table 1.
Profile of patients with eucalyptus oil–induced seizures
| Age of patient (years) | Sex | Mode of inhalation | Time to seizure (min) | Duration of seizure (min) | Type of seizure | Postictal drowsiness (min) | H/O febrile seizure | Past H/O seizure | Family H/O seizure | H/O previous use of eucalyptus oil | MRI | EEG | AED/Duration of treatment (weeks) | F/u (months) | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 | M | Inhalation | 5 | 15 | GTCS | 15 | No | No | No | No | Normal | Right frontal slowing | Levetiracetam (2 weeks) | 4 | No |
| 45 | M | Inhalation | 5 | 5 | GTCS | 20 | No | No | No | No | Normal | Normal | Levetiracetam | 3 | No |
| 30 | M | Inhalation | 2 | 5 | GTCS | 20 | No | No | No | No | Normal | Normal | Levetiracetam (4 weeks) | 3 | No |
| 2 | M | Intranasal drops | 2 | 3 | GTCS | 15 | No | No | No | No | Normal | Normal | No treatment | 3 | No |
| 30 | M | Inhalation | 5 | 3 | GTCS | 30 | No | No | No | No | Normal | Normal | No treatment | 12 | No |
| 11 | M | Inhalation | 3 | 3 | GTCS | 30 | No | No | No | No | Normal | Bifrontal and temporal slowing | Levetiracetam (4 weeks) | 4 | No |
| 8 | M | Massage | 10 | 8 | CPS (patient was in a state of altered sensorium for 10 min) | 10 | No | No | No | No | NA | NA | No treatment | 2 | No |
| 13 | M | Inhalation | 5 | 3 | GTCS | 20 | No | Yes | No | No | Normal | Normal | Previous topiramate continued | 12 | No |
| 39 | M | Inhalation | 2 | 1 | CPS (patient was in a state of altered sensorium for 10 min) | 10 | No | No | No | No | Normal | Normal | No treatment | 24 | No |
| 16 | M | Inhalation | 2 | 3 | GTCS | 10 | No | No | No | No | Normal | Generalized spike and wave discharges | Levetiracetam (2 weeks) | 6 | No |
AED, antiepileptic drug; CPS, complex partial seizures; EEG, electroencephalogram; F/u, follow‐up; GTCS, generalized tonic‐clonic seizures; H/O, history; NA, not available.